Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Dylan Berman

RARE PHOTOS: What s going on with uniqure stock wednesday | Rare Historical Photos

benzingaai2023_stock_market_trading_setup_close_up_of_multipl_9ea2f44f-9171-417b-a64e-58bbbd995de1_0

UniQure N.V. (NASDAQ:QURE) shares are trading higher Wednesday after the company announced positive topline results from Phase I/II study of AMT-130 in patients with Huntington’s Disease.

What To Know: The study met its primary endpoint, with high-dose AMT-130 showing a statistically significant 75% slowing of disease progression at 36 months as measured by cUHDRS compared to an external control. The therapy also achieved a key secondary endpoint, demonstrating a statistically significant 60% slowing of disease progression as measured by Total Functional Capacity.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.